final ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Similar documents
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in May 2013.

Hypromellose Eye Drops BP 0.3% w/v PL 23097/0006

PACKAGE LEAFLET: INFORMATION FOR THE USER. PARACETAMOL MACOPHARMA 10 mg/ml, solution for infusion. Paracetamol

SUMMARYOF PRODUCT CHARACTERISTICS

Dechra Veterinary Products Limited (A business unit of Dechra Pharmaceuticals PLC) Sansaw Business Park Hadnall, Shrewsbury Shropshire SY4 4AS

SUMMARY OF PRODUCT CHARACTERISTICS

Perfalgan 10 mg/ml, solution for infusion

Having regard to the Treaty establishing the European Economic Community, and in particular Article 100 thereof;

PACKAGE LEAFLET: INFORMATION FOR THE USER. VITAMINE B12 STEROP 1mg/1ml Solution for injection / oral solution. Cyanocobalamin

AQUATIC ANIMAL MEDICINE RECORD BOOK

Always take this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse have told you.

Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab

ZOVIRAX Cold Sore Cream

NEUROTONE THR 00904/0005 UKPAR

Nevirapine 200 mg tablets WHOPAR part 5 09/2010, version 1.0 (Matrix Laboratories Ltd), HA396 LABELLING. Page 1 of 8

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands

Summary of Product Characteristics

The format of this leaflet was determined by the Ministry of Health and its content was checked and approved in September 2008 HAVRIX 1440

The clinical studies have been performed in children, adolescents and adults, from 4 years up to 55 years of age.

Package leaflet: Information for the patient. Naloxone Hydrochloride 20 micrograms / ml Solution for Injection Naloxone hydrochloride

MUTUAL RECOGNITION PROCEDURE DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

skin and soft tissue infections (skinfold pyoderma, impetigo, folliculitis, furunculosis, cellulitis) caused by susceptible strains of organisms.

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

IMPORTANT: PLEASE READ

SUMMARY OF PRODUCT CHARACTERISTICS

ROFERON-A PFS 3 M IU/0.5 ml

One vial contains 500 U* of C1-inhibitor** After reconstitution the product contains 500 U/5 ml which correspond to a concentration of 100 U/ml.

I B2.4. Design of the patient information leaflet for VariQuin

MENINGOCOCCAL GROUP B VACCINE (BEXSERO) Information for Health Professionals

Footvax. First for footrot. The Sheep Farmer s Guide to: FOOTROT. and its control

Felimazole 5 mg Coated Tablet

College ter Beoordeling van Geneesmiddelen (CBG) Medicines Evaluation Board (MEB) Graadt van Roggenweg AH Utrecht The Netherlands

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

SUMMARY OF PRODUCT CHARACTERISTICS. Albuman 200 g/l is a solution containing 200 g/l (20%) of total protein of which at least 95% is human albumin.

Package Leaflet: Information for the user

Decentralised Procedure. Public Assessment Report. Paracetamol-ratiopharm 10 mg/ml Infusionslösung Paracetamol DE/H/1908/001/DC

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON HYPERICUM PERFORATUM L., HERBA (TRADITIONAL USE)

Somulose, 400 mg/25 mg/ml, Avlivningsvätska för djur Secobarbital Sodium. Applicant: Dechra Limited

MACROGOL COMPOUND ORAL POWDER (sodium chloride, sodium hydrogen carbonate, potassium chloride, macrogol 3350) PL 33579/0001 UKPAR TABLE OF CONTENTS

TdaP-Booster (tee-dee-ay-pee boo-ster)

Arnicare Arnica 30c pillules NR 01175/0181 UKPAR

Beclometasone Dipropionate 50 micrograms per spray Aqueous Nasal Spray PL 16431/0178

SUMMARY OF PRODUCT CHARACTERISTICS

Package leaflet: Information for the patient. Laxido Orange, powder for oral solution

If you forget to use Catacrom Eye Drops If you forget to use this medicine, use it as soon as you remember.

COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) FINAL COMMUNITY HERBAL MONOGRAPH ON AVENA SATIVA L., FRUCTUS

Thioctacid 600 T Solution for Injection contains 600 mg alpha-lipoic acid

Summary of Product Characteristics Medical Helium

1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Package leaflet : information for the user. Dilute Adrenaline/Epinephrine Injection 1:10,000 adrenaline (epinephrine) (as acid tartrate) 0.

160S01105, Page 1 of 7. Human Hepatitis B Immunoglobulin, solution for intramuscular injection.

RECONSTITUTING MEDICATIONS: HOW TO FLUFF UP MEDICATIONS

PACKAGE LEAFLET: INFORMATION FOR THE USER. STAMARIL, powder and solvent for suspension for injection in pre-filled syringe Yellow fever vaccine (Live)

Omeprazole 20 mg gastro-resistant tablets PL 14017/0277

YOUR GUIDE TO THE LANTUS SOLOSTAR INSULIN PEN

Memantine hydrochloride 20 mg film-coated tablets PL 17907/0291

Promoting safer use of injectable medicines

Donepezil hydrochloride 10 mg film-coated tablets PL 19156/0130

SUMMARY OF PRODUCT CHARACTERISTICS. Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE)

Mucodyne-Clear 250 mg/5 ml Syrup PL 04425/0665

Medicine Record Book

Tell your doctor about all the medicines you take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Paracetamol RETINO - SCREENED 20% PACKAGE LEAFLET: INFORMATION FOR THE USER. 10 mg/ml, solution for infusion

SODIUM CHLORIDE 0.9% W/V SOLUTION FOR INJECTION PL 01502/0068 UKPAR TABLE OF CONTENTS

Summary of Product Characteristics Medical Air

Reconstitution of Solutions

Public Assessment Report. Decentralised Procedure

Montelukast 10mg film-coated tablets PL 17907/0474

[For POM]: Read all of this leaflet carefully before you start using this medicine.

Code of Practice on the responsible use of animal medicines on the farm

DUKORAL Oral inactivated cholera vaccine. Australian PI

Item 2 Guidelines for the Production of Polyclonal and Monoclonal Antibodies in Rodents and Rabbits

1 NAME OF THE MEDICINAL PRODUCT 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

PACKAGE LEAFLET: INFORMATION FOR THE USER. /.../ 2.5 mg orodispersible tablets. Desloratadine

Importer / Manufacturer: MSD (THAILAND) LTD./ Merck & Co.,Inc., West Point, Pennsylvania SUMMARY OF PRODUCT CHARACTERISTICS

N HUMAN Novo Nordisk Patient Information for Novolin N

UKPAR Goodnight THR 00904/0003. Goodnight THR 00904/0003 UKPAR TABLE OF CONTENTS. Lay Summary Page 2. Scientific discussion Page 3

CMD(v)/GUI/014. GUIDANCE for The Processing of Generic Applications Through MRP / DCP

NEW ZEALAND DATA SHEET NAPHCON-A Naphazoline hydrochloride and pheniramine maleate.

PACKAGE LEAFLET

DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

2 What you need to know before you have Ampiclox

Package leaflet: Information for the user

STELARA INJECTION. What is in this leaflet. Before you use STELARA. What STELARA is used for. Consumer Medicine Information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ADRENALINE (TARTRATE) STEROP 1 mg/1 ml Solution for injection. Adrenaline (Levorenine, Epinephrine)

LEMSIP MAX DAY & NIGHT COLD & FLU RELIEF CAPSULES. (paracetamol, caffeine and phenylephrine hydrochloride)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Elidel 10 mg/g Cream. pimecrolimus

BVA. British Trout Association

For use during the NH season

Community herbal monograph on Commiphora molmol Engler, gummi-resina

ISOPLEX 4% W/V SOLUTION FOR INFUSION (Succinylated gelatin) PL 13538/0017 UKPAR TABLE OF CONTENTS

1. What Xylocaine with adrenaline is and what it is used for

Public Assessment Report. Decentralised Procedure

Package Leaflet: Information for the user Propecia 1 mg film-coated Tablets Finasteride

PATIENT INFORMATION LEAFLET. Forceval Capsules

used to treat inflammation, corneal injury and bacterial infections in the external part of the eye.

Transcription:

hyogen-spc-en-2015-03-27-clean- [Version 8, 10/2012] final ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1

1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hyogen emulsion for injection for pigs FI, SE: Hyobloc DK: Mhyogen BE, NL: Hyogen J5 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One dose (2 ml) contains: Active substance: Inactivated Mycoplasma hyopneumoniae 2940 strain: min. 5.5 EU * Adjuvants: Light liquid paraffin 187 μl Escherichia coli J5 LPS 1184-38000 Endotoxin unit Excipient: Thiomersal 50 µg * Mean antibody titre expressed in M. hyopneumoniae ELISA Unit obtained 28 days after the immunisation of rabbits with half of pig vaccine dose (1ml). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Emulsion for injection Off-white, homogeneous emulsion. 4. CLINICAL PARTICULARS 4.1 Target species Pigs for fattening 4.2 Indications for use, specifying the target species For the active immunization of fattening pigs from 3 weeks of age to reduce the occurrence and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. Onset of immunity: 3 weeks after the vaccination Duration of immunity: 26 weeks after vaccination 4.3 Contraindications None. 4.4 Special warnings for each target species None. 2

4.5 Special precautions for use Special precautions for use in animals Vaccinate only healthy animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. To the user: This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again. To the physician: This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert and PROMPT surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon. 4.6 Adverse reactions (frequency and seriousness) On the day of vaccination a transient mean increase in body temperature of about 1.3 C is very common. In an individual pig this increase might reach 2oC, but in all cases body temperature is back to normal the next day. A local reaction at the site of injection in the form of a swelling of a diameter up to 5 cm can be very common, which can last for three days. These reactions are of transient nature and do not need further treatment. Immediate mild hypersensitivity-like reactions may occur uncommonly after vaccination, resulting in transient clinical signs such as vomiting. These clinical signs normally resolve without treatment The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). 4.7 Use during pregnancy, lactation or lay Not applicable. 4.8 Interaction with other medicinal products and other forms of interaction. 3

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 4.9 Amounts to be administered and administration route For intramuscular use. Vaccinate pigs in the side of their neck. Administer a single dose of 2 ml from 3 weeks of age. The data available are not sufficient to exclude the interaction of maternally derived antibodies with vaccine uptake. Interaction with maternal-derived antibodies is known and should be taken into consideration. It is recommended to delay vaccination in piglets with residual MDA at the age of 3 weeks. Shake well before use. Use sterile syringe and needle, respect aseptic conditions of vaccination. 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary As the vaccine is inactivated, studies investigating the safety of an overdose administration are not required. 4.11 Withdrawal period(s) Zero days. 5. IMMUNOLOGICAL PROPERTIES Pharmacotherapeutic group: Pig / Inactivated bacterial vaccines / mycoplasma ATCvet code: QI09AB13 Inactivated bacterial vaccine, containing whole cell concentrate of Mycoplasma hyopneumoniae strain 2940. This antigen is incorporated in an adjuvant for stimulation of immunity, based on a combination of light liquid paraffin and cell free Escherichia coli J5 LPS. The product stimulates the development of active immunity in pigs against Mycoplasma hyopneumoniae. Under experimental conditions reduction of M. hyopneumoniae colonization was demonstrated 44-50 days post vaccination. 6. PHARMACEUTICAL PARTICULARS 6.1 List of excipients light liquid paraffin sorbitan trioleate Polysorbate 80 Escherichia coli J5 LPS thiomersal sodium chloride potassium chloride disodium phosphate dihydrate potassium dihydrogen phosphate water for injection 6.2 Incompatibilities 4

Do not mix with any other veterinary medicinal product. 6.3 Shelf life Shelf life of the veterinary medicinal product as packaged for sale: 15 months Shelf life after first opening the immediate packaging: 10 hours 6.4. Special precautions for storage Store and transport refrigerated (2 C 8 C). Do not freeze. Protect from light. 6.5 Nature and composition of immediate packaging Low density polyethylene bottle of 50, 100 or 250 ml volume, sealed with rubber stopper and aluminium cap. 1x50 ml, 1x100 ml, 1x250 ml, 5x50 ml, 5x100 ml or 5x250 ml in a carton box. Not all pack sizes may be marketed. 6.6 Special precautions for the disposal of unused ve terinary medicinal product or waste materials derived from the use of such products Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 7. MARKETING AUTHORISATION HOLDER 8. MARKETING AUTHORISATION NUMBER(S) 9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: DD/MM/YYYY 10 DATE OF REVISION OF THE TEXT MM/YYYY PROHIBITION OF SALE, SUPPLY AND/OR USE Not applicable. 5

ANNEX III LABELLING AND PACKAGE LEAFLET 6

A. LABELLING 7

PARTICULARS TO APPEAR ON THE OUTER PACKAGE AND THE IMMEDIATE PACKAGE 1x50, 1x100, 1x250, 5x50, 5x100, 5x250 ml carton box 100 or 250 ml bottle 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hyogen emulsion for injection for pigs 2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES One dose (2 ml) contains: Mycoplasma hyopneumoniae 2940 strain: 5.5 ELISA Units Oil adjuvant Thiomersal 50 µg 3. PHARMACEUTICAL FORM Emulsion for injection 4. PACKAGE SIZE 50 ml 100 ml 250 ml 5x50 ml 5x100 ml 5x250 ml 5. TARGET SPECIES Pigs for fattening. 6. INDICATION(S) 7. METHOD AND ROUTE(S) OF ADMINISTRATION For intramuscular use. Read the package leaflet before use and disposal. 8. WITHDRAWAL PERIOD Withdrawal period: Zero days. 9. SPECIAL WARNING(S), IF NECESSARY 8

Accidental injection is dangerous. 10. EXPIRY DATE EXP {month/year} Once opened, use by 10 hours. 11. SPECIAL STORAGE CONDITIONS Store and transport refrigerated (2 C 8 C). Do not freeze. Protect from light. 12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY 13. THE WORDS FOR ANIMAL TREATMENT ONLY AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE For animal treatment only. To be supplied only on veterinary prescription. 14. THE WORDS KEEP OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER {Name and address} <{Tel.}> <{Fax}> <{E-mail}> 16. MARKETING AUTHORISATION NUMBER(S) 17. MANUFACTURER S BATCH NUMBER Lot {number} 9

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 50, ml bottle 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Hyogen emulsion for injection for pigs 2. QUANTITY OF THE ACTIVE SUBSTANCE(S) Mycoplasma hyopneumoniae 2940 strain: 5.5 ELISA unit / dose 3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 50 ml 4. ROUTE(S) OF ADMINISTRATION IM 5. WITHDRAWAL PERIOD Withdrawal period: Zero days. 6. BATCH NUMBER Lot {number} 7. EXPIRY DATE EXP {month/year} Once opened use by 10 hours. 8. THE WORDS FOR ANIMAL TREATMENT ONLY For animal treatment only. 10

B. PACKAGE LEAFLET 11

PACKAGE LEAFLET FOR: Hyogen emulsion for injection for pigs 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Manufacturer responsible for batch release: Ceva-Phylaxia Co. Ltd. 1107 Budapest Szállás u. 5. Hungary 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Hyogen emulsion for injection for pigs 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) One dose (2 ml) contains: Active substance: Inactivated Mycoplasma hyopneumoniae 2940 strain: Adjuvants: Light liquid paraffin Escherichia coli J5 LPS Excipient: Thiomersal 50 µg min. 5.5 EU* 187 μl 1184-38000 Endotoxin unit * Mean antibody titre expressed in M. hyopneumoniae ELISA Unit obtained 28 days after the immunisation of rabbits with half of pig vaccine dose (1ml). Off-white, homogeneous emulsion. 4. INDICATION(S) For the active immunization of fattening pigs from 3 weeks of age to reduce the occurrence and severity of lung lesions caused by Mycoplasma hyopneumoniae infection. Onset of immunity: 3 weeks after the vaccination Duration of immunity: 26 weeks after vaccination 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS 12

On the day of vaccination a transient mean increase in body temperature of about 1.3 o C is very common. In an individual pig this increase might reach 2 o C, but in all cases body temperature is back to normal the next day. A local reaction at the site of injection in the form of a swelling of a diameter up to 5 cm can be very common, which can last for three days. These reactions are of transient nature and do not need further treatment. Immediate mild hypersensitivity-like reactions may occur uncommonly after vaccination, resulting in transient clinical signs such as vomiting. These clinical signs normally resolve without treatment The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) - common (more than 1 but less than 10 animals in 100 animals) - uncommon (more than 1 but less than 10 animals in 1,000 animals) - rare (more than 1 but less than 10 animals in 10,000 animals) - very rare (less than 1 animal in 10,000 animals, including isolated reports). If you notice any serious effects or other effects not mentioned in this package leaflet, please inform your veterinary surgeon. 7. TARGET SPECIES Pigs for fattening 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION For intramuscular use. Vaccinate pigs in the side of their neck. Administer a single dose of 2 ml from 3 weeks of age. The data available are not sufficient to exclude the interaction of maternally derived antibodies with vaccine uptake. Interaction with maternal-derived antibodies is known and should be taken into consideration. It is recommended to delay vaccination in piglets with residual MDA at the age of 3 weeks. 9. ADVICE ON CORRECT ADMINISTRATION Shake well before use. Use sterile syringe and needle, respect aseptic conditions of vaccination. 10. WITHDRAWAL PERIOD Zero days. 11. SPECIAL STORAGE PRECAUTIONS Keep out of the sight and reach of children. Store and transport refrigerated (2 C 8 C). Do not freeze. 13

Protect from light. Do not use this veterinary medicinal product after the expiry date which is stated on the label. Shelf life after first opening the container: 10 hours 12. SPECIAL WARNING(S) Special warnings for each target species: None. Special precautions for use in animals Vaccinate only healthy animals. Special precautions to be taken by the person administering the veterinary medicinal product to animals In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. To the user: This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again. To the physician: This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert and PROMPT surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon. Pregnancy and lactation: Not applicable. Interaction with other medicinal products and other forms of interaction: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. Overdose (symptoms, emergency procedures, antidotes): As the vaccine is inactivated, studies investigating the safety of an overdose administration are not required. Incompatibilities: Do not mix with any other veterinary medicinal product. 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY 14

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements. 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED MM/YYYY 15. OTHER INFORMATION Immunological properties: Inactivated, bacterial vaccine, containing whole cell concentrate of Mycoplasma hyopneumoniae strain 2940. This antigen is incorporated in an adjuvant for stimulation of immunity, based on a combination of light liquid paraffin and cell free Escherichia coli J5 LPS. The product stimulates the development of active immunity in pigs against Mycoplasma hyopneumoniae. Under experimental conditions reduction of M. hyopneumoniae colonization was demonstrated 44-50 days post vaccination. Pack sizes: 50, 100 or 250 ml in polyethylene bottle. 1x50 ml, 1x100 ml, 1x250 ml, 5x50 ml, 5x100 ml or 5x250 ml in a carton box. Not all pack sizes may be marketed. For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder. 15